Suplementos

← vista completa

Publicado el 1 de diciembre de 2010 | http://doi.org/10.5867/medwave.2010.11.4808

Evidencia actual de la combinación de un IDR y un ARA II/IECA

Current evidence on the combination of a direct renin inhibitor and an ARB or ACE inhibitor

Javier Díez

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Javier Díez

Facultad de Medicina, Universidad de Navarra. Pamplona, España.

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Díez J. Current evidence on the combination of a direct renin inhibitor and an ARB or ACE inhibitor. Medwave 2010;10(11):e4808 doi: 10.5867/medwave.2010.11.4808

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/12/2010

Indice

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007 Jul 21;370(9583):221-9. | CrossRef | PubMed
  2. Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, Fang H, Satlin A. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007 Dec;8(4):190-8. | CrossRef | PubMed
  3. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008 Jun 5;358(23):2433-46. | CrossRef | PubMed
  4. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 May;1(1):17-24. | CrossRef | PubMed
  5. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009 Feb 3;119(4):530-7. Epub 2009 Jan 19. | CrossRef | PubMed
  6. Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol. 2006 Mar;1(2):221-8. Epub 2005 Dec 22. | CrossRef | PubMed
  7. Ferrario CM. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control. Life Sci. 2010 Feb 27;86(9-10):289-99. Epub 2009 Dec 1. | CrossRef | PubMed
  8. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008 Dec;57(12):3297-306. Epub 2008 Oct 1. | CrossRef | PubMed
  9. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW, Dostal DE, Kumar R. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept. 2004 Aug 15;120(1-3):5-13. | CrossRef | PubMed